Loading...

Dougherty's Pharmacy

OTCPK:MYDP
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MYDP
OTCPK
$3M
Market Cap
  1. Home
  2. US
  3. Consumer Retailing
Company description

Dougherty’s Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Dougherty's Pharmacy has significant price volatility in the past 3 months.
MYDP Share Price and Events
7 Day Returns
-22.1%
OTCPK:MYDP
1.1%
US Consumer Retailing
1.6%
US Market
1 Year Returns
56.4%
OTCPK:MYDP
12.8%
US Consumer Retailing
2.6%
US Market
MYDP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dougherty's Pharmacy (MYDP) -22.1% -16.6% 0.3% 56.4% -30.1% -34.8%
US Consumer Retailing 1.1% -1.3% -2.2% 12.8% 26.5% 31.1%
US Market 1.6% -1.7% 2.1% 2.6% 38.5% 41.4%
1 Year Return vs Industry and Market
  • MYDP outperformed the Consumer Retailing industry which returned 12.8% over the past year.
  • MYDP outperformed the Market in United States of America which returned 2.6% over the past year.
Price Volatility
MYDP
Industry
5yr Volatility vs Market

MYDP Value

 Is Dougherty's Pharmacy undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dougherty's Pharmacy to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dougherty's Pharmacy.

OTCPK:MYDP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:MYDP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Consumer Retailing Unlevered Beta Simply Wall St/ S&P Global 0.47
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.47 (1 + (1- 21%) (203.09%))
1.15
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.15 * 5.96%)
9.58%

Discounted Cash Flow Calculation for OTCPK:MYDP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dougherty's Pharmacy is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:MYDP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.58%)
2019 0.20 Est @ -25.77% 0.18
2020 0.17 Est @ -17.22% 0.14
2021 0.15 Est @ -11.24% 0.11
2022 0.14 Est @ -7.05% 0.10
2023 0.13 Est @ -4.11% 0.08
2024 0.13 Est @ -2.06% 0.07
2025 0.13 Est @ -0.62% 0.07
2026 0.13 Est @ 0.38% 0.06
2027 0.13 Est @ 1.09% 0.06
2028 0.13 Est @ 1.58% 0.05
Present value of next 10 years cash flows $0.93
OTCPK:MYDP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $0.13 × (1 + 2.73%) ÷ (9.58% – 2.73%)
$1.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1.98 ÷ (1 + 9.58%)10
$0.79
OTCPK:MYDP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $0.93 + $0.79
$1.72
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1.72 / 23.08
$0.07
OTCPK:MYDP Discount to Share Price
Calculation Result
Value per share (USD) From above. $0.07
Current discount Discount to share price of $0.15
= -1 x ($0.15 - $0.07) / $0.07
-98.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dougherty's Pharmacy is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dougherty's Pharmacy's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dougherty's Pharmacy's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:MYDP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.15
OTCPK:MYDP Share Price ** OTCPK (2019-05-21) in USD $0.15
United States of America Consumer Retailing Industry PE Ratio Median Figure of 22 Publicly-Listed Consumer Retailing Companies 21.26x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.74x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dougherty's Pharmacy.

OTCPK:MYDP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:MYDP Share Price ÷ EPS (both in USD)

= 0.15 ÷ -0.15

-0.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dougherty's Pharmacy is loss making, we can't compare its value to the US Consumer Retailing industry average.
  • Dougherty's Pharmacy is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Dougherty's Pharmacy's expected growth come at a high price?
Raw Data
OTCPK:MYDP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Consumer Retailing Industry PEG Ratio Median Figure of 14 Publicly-Listed Consumer Retailing Companies 2.89x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dougherty's Pharmacy, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dougherty's Pharmacy's assets?
Raw Data
OTCPK:MYDP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.08
OTCPK:MYDP Share Price * OTCPK (2019-05-21) in USD $0.15
United States of America Consumer Retailing Industry PB Ratio Median Figure of 30 Publicly-Listed Consumer Retailing Companies 2.36x
United States of America Market PB Ratio Median Figure of 5,202 Publicly-Listed Companies 1.84x
OTCPK:MYDP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:MYDP Share Price ÷ Book Value per Share (both in USD)

= 0.15 ÷ -0.08

-1.8x

* Primary Listing of Dougherty's Pharmacy.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dougherty's Pharmacy has negative assets, we can't compare the value of its assets to the US Consumer Retailing industry average.
X
Value checks
We assess Dougherty's Pharmacy's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. Dougherty's Pharmacy has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MYDP Future Performance

 How is Dougherty's Pharmacy expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dougherty's Pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.5%
Expected Consumer Retailing industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dougherty's Pharmacy expected to grow at an attractive rate?
  • Unable to compare Dougherty's Pharmacy's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Dougherty's Pharmacy's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Dougherty's Pharmacy's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:MYDP Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 5.5%
United States of America Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 3.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:MYDP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:MYDP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 36 0 -4
2018-09-30 37 0 -4
2018-06-30 39 0 -2
2018-03-31 40 0 -2
2017-12-31 40 1 -2
2017-09-30 41 1 -5
2017-06-30 41 1 -5
2017-03-31 42 1 -5
2016-12-31 43 1 -5
2016-09-30 44 -1
2016-06-30 44 -1
2016-03-31 43 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Dougherty's Pharmacy is high growth as no earnings estimate data is available.
  • Unable to determine if Dougherty's Pharmacy is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:MYDP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Dougherty's Pharmacy Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MYDP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.15
2018-09-30 -0.19
2018-06-30 -0.10
2018-03-31 -0.10
2017-12-31 -0.09
2017-09-30 -0.22
2017-06-30 -0.21
2017-03-31 -0.21
2016-12-31 -0.21
2016-09-30 -0.04
2016-06-30 -0.03
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dougherty's Pharmacy will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Dougherty's Pharmacy's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Consumer Retailing companies here
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Dougherty's Pharmacy's filings and announcements here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Dougherty's Pharmacy's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dougherty's Pharmacy has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MYDP Past Performance

  How has Dougherty's Pharmacy performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dougherty's Pharmacy's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dougherty's Pharmacy does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Dougherty's Pharmacy's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dougherty's Pharmacy's 1-year growth to the US Consumer Retailing industry average as it is not currently profitable.
Earnings and Revenue History
Dougherty's Pharmacy's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dougherty's Pharmacy Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MYDP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 36.05 -3.53 9.25
2018-09-30 37.38 -4.38 9.78
2018-06-30 38.57 -2.33 10.13
2018-03-31 39.61 -2.21 10.33
2017-12-31 40.21 -2.11 10.40
2017-09-30 40.69 -5.01 10.36
2017-06-30 41.24 -4.79 10.20
2017-03-31 42.03 -4.81 10.26
2016-12-31 42.79 -4.86 10.45
2016-09-30 44.07 -0.85 11.00
2016-06-30 44.36 -0.66 11.18
2016-03-31 42.75 -0.41 11.00
2015-12-31 40.95 -0.40 10.63
2015-09-30 37.21 -0.20 9.82
2015-06-30 33.74 -0.05 9.04
2015-03-31 31.05 0.19 8.30
2014-12-31 28.48 0.45 7.64
2014-09-30 27.01 0.24 7.18
2014-06-30 25.86 0.32 6.94
2014-03-31 25.48 0.43 6.76
2013-12-31 25.19 0.94 6.60
2013-09-30 24.36 -2.01 6.16
2013-06-30 24.83 -2.25 6.93
2013-03-31 24.60 -2.74 7.10
2012-12-31 24.70 -3.58 7.38
2012-09-30 25.57 -1.16 8.28
2012-06-30 26.60 -1.35 8.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dougherty's Pharmacy has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Dougherty's Pharmacy has efficiently used its assets last year compared to the US Consumer Retailing industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dougherty's Pharmacy improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dougherty's Pharmacy's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dougherty's Pharmacy has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MYDP Health

 How is Dougherty's Pharmacy's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dougherty's Pharmacy's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dougherty's Pharmacy's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Dougherty's Pharmacy's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dougherty's Pharmacy's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Dougherty's Pharmacy has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dougherty's Pharmacy Company Filings, last reported 4 months ago.

OTCPK:MYDP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -1.90 6.94 0.25
2018-09-30 -1.56 6.94 0.21
2018-06-30 0.93 6.99 0.05
2018-03-31 1.36 7.34 0.06
2017-12-31 1.63 7.45 0.09
2017-09-30 2.82 7.35 0.15
2017-06-30 3.25 7.84 0.45
2017-03-31 3.55 8.07 0.52
2016-12-31 3.70 8.74 0.06
2016-09-30 7.80 8.80 0.36
2016-06-30 8.01 8.99 0.35
2016-03-31 8.33 8.11
2015-12-31 8.54 9.51 0.07
2015-09-30 8.63 8.31
2015-06-30 8.65 6.91
2015-03-31 8.72 4.90
2014-12-31 8.92 3.21 0.06
2014-09-30 8.81 3.10 0.40
2014-06-30 8.68 2.61 0.46
2014-03-31 8.52 2.29 0.58
2013-12-31 8.45 2.36 0.24
2013-09-30
2013-06-30 8.06 2.76 0.32
2013-03-31 7.78 3.01 0.10
2012-12-31 7.21 3.33 0.26
2012-09-30 14.53 3.35 0.14
2012-06-30 14.50 3.49 0.12
  • Dougherty's Pharmacy has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Dougherty's Pharmacy's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Dougherty's Pharmacy has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Dougherty's Pharmacy has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -4.3% per year.
X
Financial health checks
We assess Dougherty's Pharmacy's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dougherty's Pharmacy has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MYDP Dividends

 What is Dougherty's Pharmacy's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dougherty's Pharmacy dividends.
If you bought $2,000 of Dougherty's Pharmacy shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dougherty's Pharmacy's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dougherty's Pharmacy's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:MYDP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dougherty's Pharmacy has not reported any payouts.
  • Unable to verify if Dougherty's Pharmacy's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dougherty's Pharmacy's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dougherty's Pharmacy has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Dougherty's Pharmacy's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dougherty's Pharmacy afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dougherty's Pharmacy has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MYDP Management

 What is the CEO of Dougherty's Pharmacy's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stewart Edington
AGE 70
TENURE AS CEO 0.3 years
CEO Bio

Mr. Stewart I. Edington serves as President, Chief Executive Officer and Interim Chief Financial Officer at Dougherty's Pharmacy, Inc. since February 07, 2019 and its Director since March 2019. He joins Dougherty’s from Gelson’s Pharmacy, where he served as Director of Operations from 2016 to 2017. Previously, he was Vice President of Pharmacy Operations at Haggen Food & Pharmacy from 2015 to 2016. He served in various roles at Albertsons, including Divisional Pharmacy Manager from 2003 to 2011. He served as Vice President of Pharmacy Operations at Albertsons, LLC from August 19, 2011 to December 2013. Mr. Edington has been with Albertsons since 2003, when he served as a Pharmacy Manager in the Phoenix, Ariz., area. Since 2006, he served as Pharmacy Manager for Albertsons' Florida division. He was also an integral part of the turnaround team during his tenure at Albertsons, working closely with Cerberus Capital Management, L.P., a private equity firm that owns and operates Albertsons.

CEO Compensation
  • Insufficient data for Stewart to compare compensation growth.
  • Insufficient data for Stewart to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Dougherty's Pharmacy management team in years:

0.3
Average Tenure
63
Average Age
  • The average tenure for the Dougherty's Pharmacy management team is less than 2 years, this suggests a new team.
Management Team

Jim Leslie

TITLE
Chairman of the Board & Secretary
COMPENSATION
$101K
AGE
63

Stewart Edington

TITLE
President
AGE
70
TENURE
0.3 yrs

Katherine Burrow

TITLE
Managing Director of Business Development
TENURE
1.3 yrs

Susan Olson

TITLE
Secretary

Robin Bruce

TITLE
Controller

J.D. Abouchar

TITLE
Consultant & Advisor
AGE
58
TENURE
0.3 yrs

Rick Troberman

TITLE
Executive Vice President of Sales and Marketing
Board of Directors Tenure

Average tenure and age of the Dougherty's Pharmacy board of directors in years:

1.8
Average Tenure
68
Average Age
  • The average tenure for the Dougherty's Pharmacy board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jim Leslie

TITLE
Chairman of the Board & Secretary
COMPENSATION
$101K
AGE
63
TENURE
17.2 yrs

Stewart Edington

TITLE
President
AGE
70
TENURE
0.2 yrs

Tony LeVecchio

TITLE
Independent Director
COMPENSATION
$23K
AGE
71
TENURE
14.9 yrs

Will Cureton

TITLE
Independent Director
COMPENSATION
$13K
AGE
68
TENURE
14.3 yrs

Troy Phillips

TITLE
Independent Director
COMPENSATION
$12K
AGE
70
TENURE
1.8 yrs

Josh Womack

TITLE
Independent Director
AGE
38
TENURE
0.2 yrs

Joe Flynn

TITLE
Director
AGE
52
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Dougherty's Pharmacy insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Apr 19 Buy Troy Phillips Individual 18. Apr 19 18. Apr 19 100,000 $0.17 $17,250
11. Apr 19 Buy Troy Phillips Individual 06. Mar 19 08. Apr 19 118,750 $0.11 $12,047
X
Management checks
We assess Dougherty's Pharmacy's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dougherty's Pharmacy has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MYDP News

Simply Wall St News

MYDP Company Info

Description

Dougherty’s Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. Its flagship store is Dougherty’s Pharmacy, a turn-key multi-service pharmacy located in Dallas, Texas. The company was formerly known as Ascendant Solutions, Inc. and changed its name to Dougherty’s Pharmacy, Inc. in May 2017. Dougherty’s Pharmacy, Inc. was founded in 1929 and is based in Dallas, Texas.

Details
Name: Dougherty's Pharmacy, Inc.
MYDP
Exchange: OTCPK
Founded: 1929
$3,416,160
23,082,164
Website: http://www.doughertys.com
Address: Dougherty's Pharmacy, Inc.
5924 Royal Lane,
Suite 250,
Dallas,
Texas, 75230,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK MYDP Class A Common Stock Pink Sheets LLC US USD 11. Nov 1999
Number of employees
Current staff
Staff numbers
87
Dougherty's Pharmacy employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 03:52
End of day share price update: 2019/05/21 00:00
Last earnings filing: 2019/05/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.